WO2014127155A3 - Procédés d'identification, de prévention et de traitement du virus virulent de la maladie pieds-mains-bouche au moyen de séquences de réplikine - Google Patents

Procédés d'identification, de prévention et de traitement du virus virulent de la maladie pieds-mains-bouche au moyen de séquences de réplikine Download PDF

Info

Publication number
WO2014127155A3
WO2014127155A3 PCT/US2014/016303 US2014016303W WO2014127155A3 WO 2014127155 A3 WO2014127155 A3 WO 2014127155A3 US 2014016303 W US2014016303 W US 2014016303W WO 2014127155 A3 WO2014127155 A3 WO 2014127155A3
Authority
WO
WIPO (PCT)
Prior art keywords
mouth disease
hand foot
identifying
methods
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/016303
Other languages
English (en)
Other versions
WO2014127155A2 (fr
Inventor
Samuel Bogoch
Elenore S. Bogoch
Samuel Winston Bogoch
Anne-Elenore Bogoch Borsanyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014127155A2 publication Critical patent/WO2014127155A2/fr
Publication of WO2014127155A3 publication Critical patent/WO2014127155A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés permettant de prévoir la virulence de virus de la maladie pieds-mains-bouche et d'épidémies desdits virus, consistant à comparer les concentrations en réplikine dans différents isolats de virus et à identifier les isolats les plus virulents comme étant ceux présentant les concentrations en réplikine les plus élevées. La présente invention concerne en outre des applications diagnostiques, préventives et thérapeutiques de peptides de réplikine identifiés dans des virus de la maladie pieds-mains-bouche, notamment des peptides de réplikine identifiés comme étant partagés entre des virus responsables de la maladie pieds-mains-bouche.
PCT/US2014/016303 2013-02-15 2014-02-13 Procédés d'identification, de prévention et de traitement du virus virulent de la maladie pieds-mains-bouche au moyen de séquences de réplikine Ceased WO2014127155A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765106P 2013-02-15 2013-02-15
US61/765,106 2013-02-15

Publications (2)

Publication Number Publication Date
WO2014127155A2 WO2014127155A2 (fr) 2014-08-21
WO2014127155A3 true WO2014127155A3 (fr) 2014-12-04

Family

ID=51354677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/016303 Ceased WO2014127155A2 (fr) 2013-02-15 2014-02-13 Procédés d'identification, de prévention et de traitement du virus virulent de la maladie pieds-mains-bouche au moyen de séquences de réplikine

Country Status (1)

Country Link
WO (1) WO2014127155A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151677A1 (en) * 2001-03-27 2002-10-17 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
WO2012108840A1 (fr) * 2011-02-08 2012-08-16 Temasek Life Sciences Laboratory Limited Nouvelle cassette d'expression pour une présentation en surface efficace des protéines antigéniques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151677A1 (en) * 2001-03-27 2002-10-17 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
WO2012108840A1 (fr) * 2011-02-08 2012-08-16 Temasek Life Sciences Laboratory Limited Nouvelle cassette d'expression pour une présentation en surface efficace des protéines antigéniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANG, LY ET AL.: "Viral Virulence Factors: EV71 Genetics Of 3C And Its Correlation With Clinical Outcome: 3C Protein", PARTIAL [ENTEROVIRUS A71 *
DATABASE GENBANK 26 July 2006 (2006-07-26), accession no. BG78216 *

Also Published As

Publication number Publication date
WO2014127155A2 (fr) 2014-08-21

Similar Documents

Publication Publication Date Title
MX392028B (es) Vacunas para el tratamiento y prevención del cáncer.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
WO2014127917A8 (fr) Combinaison d'une vaccination et de l'inhibition de la voie de pd-1
GEAP202114794A (en) Antibody neutralizing human respiratory syncytial virus
WO2015024668A3 (fr) Vaccin contre le virus respiratoire syncytial
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
NZ730763A (en) Methods of treating a tauopathy
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
WO2013106689A8 (fr) Inhibiteurs de la protéase ns3 du vhc
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
MX369195B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
IL247704A0 (en) Amide compounds, methods for their preparation and use as substances for the treatment and prevention of diseases caused by viruses containing RNA and/or DNA and associated diseases
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2014160987A3 (fr) Vaccins comprenant des polypeptides de leishmania pour le traitement et le diagnostic de la leishmaniose
CL2016000300A1 (es) Métodos terapéuticos
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2014160985A3 (fr) Vaccins comprenant des polypeptides de leishmania pour le traitement et le diagnostic de la leishmaniose
EA201491668A1 (ru) Вакцины и способы для лечения болезни лайма у собак

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14751461

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14751461

Country of ref document: EP

Kind code of ref document: A2